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Abstract: - The aim of the study was to monitor the prevalence of anaemia in chronic kidney disease in a tertiary care hospital. A 
prospective, observational, cross-sectional study was conducted on patients who visited to tertiary care hospital between November 
2019 to April 2020, with a sample size of 150. A total of 150 pts were included in the study, of those 22% (33 pts) have no other 
comorbidities, 23.3% (35 pts) also have hypertension alone and 35.3% (53 pts) have diabetes and 19.3% (29 pts) have both diabetes 
and hypertension. Of these 65.3% (98 pts) have glomerular filtration rate (GFR) less than 15 ml/min, 14% (21 pts) have GFR between 
15-29 ml/min, 9.3% (14 pts) have GFR between 30-59 ml/min, 6% (9 pts) have GFR in between 60-80 ml/min and 5.3% (8 pts) 
have GFR greater than 90 ml/min. In the present study, 81 pts (54%) were suffering from anaemia. This study concludes that anaemia 
is more prevalent in chronic kidney disease conditions and glomerular filtration rate is the key factor to assess the disease progression 
and estimate the relation between the developments of anaemia in kidney failure condition, as the kidney function gets decreased, 
the risk for development of anaemia gets increased.    
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I. INTRODUCTION 
The kidneys function as filters of the blood, removing 
waste products and controlling the balance of fluid and 
electrolytes. Filtration occurs via bundles of capillaries called 
glomeruli (singular, glomerulus). A reduction in the glomerular 
filtration rate (GFR) to 60 mL/min/1.73 m2 indicates chronic 
kidney disease (CKD), as do structural or functional renal 
abnormalities, which may be present in people with normal 
GFR [1]. 
One of the lesser-known functions of the kidneys is the 
production of erythropoietin, a signalling molecule that 
stimulates red blood cell production, in response to decreased  
 
oxygen levels in the blood. Any disruption of this process, e.g., 
secondary to a functional abnormality due to CKD, has the 
potential to produce anaemia, a condition in which the number 
of circulating red blood cells, and therefore the level of 
haemoglobin, is lower than normal [2]. 
Anaemia is a well-known complication in chronic kidney dis-
ease (CKD) and is associated with progression of CKD, poor 
quality of life, and increase in morbidity and mortality [2-6]. 
The mechanism of anaemia in CKD is multifactorial: 
erythropoietin deficiency from reduced renal mass, iron and 
nutritional deficiencies, various pro-inflammatory mediators 
commonly elevated in CKD may affect the erythropoiesis in 
CKD [7]. 
Other possible causes of anaemia in CKD include iron 
deficiency, inflammation, and the accumulation of uremic 
toxins [2,8]. Thus, the abnormal composition of blood or urine 
is an additional indicator of kidney damage. 
Anaemia in CKD is associated with cognitive impairment, 
sleep disturbances, CKD progression, cardiovascular 
comorbidities, and higher mortality [2,3,9,10]. Direct 
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healthcare costs are higher in CKD patients with anaemia than 
in those without [3], and quality of life issues (e.g., fatigue, 
reduced productivity) are common [2,9]. The prevalence of 
anaemia (with or without CKD) increases with age [11,12], 
which means that, as the US population ages, the number of 
people affected by anaemia in CKD will also increase. 
 
1.1 Impact of Anaemia 
 
The impact of anaemia on patients with CKD is 
profound. In addition to the well-known symptoms of fatigue, 
dizziness, and shortness of breath, anaemia has been associated 
with more severe adverse outcomes, such as cardiovascular 
complications including left ventricular hypertrophy and 
congestive heart failure. In patients with diabetes, anaemia has 
been associated with a decline in kidney function, which often 
occurs in patients with diabetes. Hypoxia caused by anaemia 
stimulates the renin-angiotensin-aldosterone system and 
contributes to renal vasoconstriction. These factors further 
exacerbate proteinuria by increasing protein in the renal tubules 
in patients with diabetes [13]. Of note, in patients with type 2 
diabetes, anaemia has been shown to be an independent risk 
factor associated with the loss of kidney function [14]. In 
patients with diabetes, anaemia can also contribute to the 
severity of cardiovascular disease and independently increase 
the risk of retinopathy. Anaemia is also thought to hasten the 
progression of diabetic neuropathy [14]. Other general 
complications associated with anaemia include reduced 
cognitive function and mental acuity, impaired quality of life, 
and the need for blood transfusions [15-18]. 
Correction of anaemia has been shown to improve cardiac 
function possibly by reducing exercise-induced myocardial 
ischemia [15]. Treatment of anaemia associated with CKD has 
also been shown to result in improvements in exercise capacity; 
physical performance features such as endurance; energy; and 
physical mobility [16]. Patient satisfaction increases when 
anaemia is corrected, as evidenced by higher quality-of-life 
scores, improved sexual function, better cognition, less 
depression, and better socialization [17]. In non–dialysis-
dependent CKD patients, stabilization of renal function has 
been associated with the treatment of the anaemia of CKD [15]. 
Finally, treatment of anaemia has been shown to reduce 
hospitalization and mortality rates [18]. 
As a result of the potentially severe consequences of anaemia 
in CKD, early recognition and management of anaemia are 
imperative. Consequently, monitoring Hb and detecting 
anaemia in patients with diabetes is essential. 
II. MATERIALS AND METHODS 
In a tertiary care hospital, at the nephrology 
department, a prospective, observational, cross-sectional study 
was conducted on patients visited between November 2019 to 
April 2020, with a sample size of 150. Data was collected from 
the case sheets available in wards and followed. Patients of all 
age groups, both males and females of CKD patients with other 
comorbidities were included in the study. Patients from the 
outpatient department, pregnant women, and patients with other 
kidney problems were excluded from the study and the data was 
analyzed by using SPSS software. 
III. RESULTS 
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Demographic details reveal that the patients of age between 51-
65 were more (73 patients) followed by 36-50 (59 patients), 
then 66-80 (11 patients) and 20-35 (7 patients). This describes 
the effect of the age factor on disease distribution. 
Analysis of 150 patients diagnosed with CKD in nephrology 
department during our study period reveals that prevalence was 
more in males (92) than females (58). 
According to social history, it was found that 38 patients 
(25.33%) were smokers, 4 patients (2.66%) were alcoholics, 48 
patients (32%) have both smoking and alcohol habits, and 60 
patients (40%) doesn't smoke or consume alcohol. 
Table.1. Distribution of comorbid diseases 
In many patients (88%) along with the main diagnosis, 
comorbid conditions were observed. Of those, Diabetes 
Mellitus was the most common comorbid condition (35.33%), 
followed by Hypertension (23.33%) and both diabetes mellitus 
and hypertension (19.33%) were observed. 




Of 150 patients, 98 patients (65.33%) have GFR less than 15 
ml/min, followed by 21 patients (14%) with GFR ranges from 
15-29 ml/min, 14 patients (9.33%) with GFR range of 30-59 
ml/min, 9 patients (6%) with GFR range of 60-80 ml/min and 
8 patients (5.33%) with GFR greater than 90 ml/min.  
Comorbidities No of 
persons 
Percent 
DM 53 35.33% 
HTN 35 23.33% 
DM & HTN 29 19.33% 
None 33 22% 
Total 150 100% 
 
GFR No of 
persons 
Percentage 
>90 8 5.33% 
60 – 80 9 6% 
30 – 59 14 9.33% 
15 – 29 21 14% 
< 15 98 65.33% 
Total 150 100% 
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Anaemia is a common condition associated with chronic kidney 
disease. Of 150 patients, 78 patients (52%) were observed with 
anaemia and  72 patients (48%)  don't have anaemia at the time 
of the study period. 
IV. CONCLUSION 
Our study concludes that anaemia is more prevalent in 
chronic kidney disease conditions and glomerular filtration rate 
is the key factor to assess the disease progression and estimate 
the relation between the development of anaemia in kidney 
failure condition, as the kidney function gets decreased, the risk 
for development of anaemia gets increased. 
REFERENCES   
[1]. National Kidney Foundation (2002) K/DOQI Clinical 
Practice Guidelines for Chronic Kidney Disease: 
Evaluation, Classification, and Stratification. Am J Kidney 
Dis 39: S1–S 266. 
[2]. Smith RE, Jr. (2010) the clinical and economic burden of 
anemia. Am J Manag Care 16 Suppl Issues: S59–66. 
[3]. van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. 
Burden of illness for patients with non-dialysis chronic 
kidney disease and anemia in the United States: a review of 
the literature. J Med Econ 2010; 13: 241-56. 
[4]. Farag YM, Keithi-Reddy SR, Mittal BV, Surana SP, 
Addabbo F, Goligorsky MS, Singh AK. Anemia, 
inflammation and health-related quality of life in chronic 
kidney disease patients. Clin Nephrol 2011; 75: 524-33. 
[5]. Iseki K, Kohagura K. Anemia as a risk factor for chronic 
kidney disease. Kidney Int Suppl 2007: S4-9. 
[6]. Kurella Tamura M, Vittinghoff E, Yang J, Go AS, Seliger 
SL, Kusek JW, Lash J, Cohen DL, Simon J, Batuman V, et 
al. Anemia and risk for cognitive de¬cline in chronic kidney 
disease. BMC Nephrol 2016; 17: 13. 
[7]. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am 
Soc Nephrol 2012; 23: 1631-4. 
[8]. National Kidney Foundation (2006) KDOQI Clinical 
Practice Guidelines and Clinical Practice Recommendations 
for Anemia in Chronic Kidney Disease. Am J Kidney Dis 
47: S11–145. 
[9]. Mehdi U, Toto RD (2009) Anemia, diabetes, and chronic 
kidney disease. Diabetes Care 32: 1320–1326. 
[10]. Herzog CA, Muster HA, Li S, Collins AJ (2004) Impact of 
congestive heart failure, chronic kidney disease, and anemia 
on survival in the Medicare population. J Card Fail 10: 467–
472. 
[11]. Bowling CB, Inker LA, Gutierrez OM, Allman RM, 
Warnock DG, et al. (2011) Age-specific associations of 
reduced estimated glomerular filtration rate with concurrent 
chronic kidney disease complications. Clin J Am Soc 
Nephrol 6: 2822–2828. 
[12]. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois 
RW (2005) Economic burden of anemia in an insured 
population. J Manag Care Pharm 11: 565–574. 
[13]. Al-Khoury S, Afzali B, Shah N, Thomas S, Gusbeth-
Tatomir P, Goldsmith D, Covic A: Diabetes, kidney disease 
and anemia: time to tackle a troublesome triad? Int J Clin 
Pract 61:281–289, 2007. 
[14]. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner 
BM, Toto RD: Anemia and endstage renal disease in patients 
with type 2 diabetes and nephropathy. Kidney Int 66:1131– 
1138, 2004. 
[15]. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, 
Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, 
No of CKD 
patients 
No of persons Percentage 
Anemia 78 52% 
No anemia 72 48% 
Total 150 100% 
 
 INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN SCIENCE AND ENGINEERING, VOL.2, NO.11, NOVEMBER 2021. 
  
HEMA MANOGNA NARNE, et.al.: UBIQUITOUSNESS OF ANAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN TERTIARY CARE 
HOSPITAL: A PROSPECTIVE OBSERVATIONAL STUDY 46 
 
Schwartz I, Steinbruch S, Iaina A: The effect of correction 
of anemia in diabetics and non-diabetics with severe 
resistant congestive heart failure and chronic renal failure by 
subcutaneous erythropoietin and intravenous iron. Nephrol 
Dialysis Transplant 18:141–146, 2003. 
[16]. Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, 
Haskell W: Effects of exercise training plus normalization 
of hematocrit on exercise capacity and health-related quality 
of life. Am J Kidney Dis 39:257–265, 2002. 
[17]. Valderrabano F, Jofre R, Lopez-Gomez JM: Quality of life 
in end-stage renal disease patients. Am J Kidney Dis 
38:443–464, 2001. 
[18]. Pisioni RL, Bragg-Gresham JL,Young EW, Akizawa T, 
Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, 
Mendelssohn DC, Held PJ, Port FK: Anemia management 
and outcomes from 12 countries in the Dialysis Outcomes 
and Practice Patterns Study (DOPPS). Am J Kidney Dis 
44:94–111, 2004. 
 
 
 
